-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Integrated Biopharma Inc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q3 2018 to Q3 2024.
- Integrated Biopharma Inc Deferred Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $197K, a 2363% increase year-over-year.
- Integrated Biopharma Inc annual Deferred Income Tax Expense (Benefit) for 2024 was $125K, a 73.6% increase from 2023.
- Integrated Biopharma Inc annual Deferred Income Tax Expense (Benefit) for 2023 was $72K.
- Integrated Biopharma Inc annual Deferred Income Tax Expense (Benefit) for 2022 was -$1.53M, a 10.5% decline from 2021.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)